Core Viewpoint - The company, Kang Le Wei Shi, has announced the suspension of clinical trials for its three-valent and nine-valent HPV vaccines due to overdue funding and financial pressures, which have been a recurring issue for the company [1][4]. Group 1: Clinical Trial Suspension - The clinical trials for the three-valent and nine-valent HPV vaccines have been paused by the Shanxi and Jiangsu Provincial Centers for Disease Control due to overdue clinical trial funding [1]. - The three-valent HPV vaccine's phase III clinical trial is expected to reach its pathological endpoint (CIN2+) by August 2024, and the suspension is not anticipated to significantly impact the accumulated qualified cases or the upcoming Biologics License Application (BLA) [2]. - The nine-valent HPV vaccine (female indication) has completed the primary endpoint case collection but may face challenges in secondary endpoint case collection and BLA submission if the trial does not resume soon [3]. Group 2: Financial Challenges - The company has faced significant financial pressure, previously announcing issues with repaying bank loans and having multiple bank accounts frozen due to liquidity problems [4]. - As of December 31, 2024, the company's cash balance was 77.77 million yuan, with total current assets of 117 million yuan, and by September 30, 2025, cash had decreased to 6.32 million yuan, a 91.88% year-on-year decline [5]. - The company has yet to commercialize its core products, with revenue primarily from research testing reagents, reporting revenues of 885,600 yuan in 2024 and a net loss of 357 million yuan [5].

Core Insights - The HPV vaccine sales slump is leading to significant financial losses for companies in the sector, particularly for Zhifei Biological, which anticipates a net loss of 10.698 billion to 13.726 billion yuan in 2025 [1][2] - The HPV vaccine market is experiencing a shift from a blue ocean to a red ocean, with increased competition from domestic vaccine manufacturers reducing the first-mover advantage previously held by Zhifei Biological [2] Company-Specific Insights - Zhifei Biological's major products, the four-valent and nine-valent HPV vaccines, have seen sales underperform due to declining public willingness to get vaccinated and increased vaccine hesitancy [2] - The company has reported its first loss since it began selling HPV vaccines in 2017, following years of profitability that peaked at over 10 billion yuan in 2021 [1] - The stock price of Zhifei Biological has significantly decreased from a peak of 152.06 yuan per share in June 2021 to 17.56 yuan per share currently [5] Industry Insights - The number of HPV vaccines available in China has reached seven, with price competition intensifying as public procurement prices for some vaccines have dropped to 27.5 yuan per dose [2] - Companies involved in HPV vaccine research, such as Kangla Weishi, are facing funding challenges that have led to the suspension of clinical trials for their HPV vaccines [3][4] - The overall market for HPV vaccines is experiencing a slowdown in growth due to factors such as reduced demand for vaccinations and increased competition, making it harder for companies to attract investment [5]

Core Viewpoint - The company, 康乐卫士, has announced the suspension of its Phase III clinical trials for both the trivalent and nine-valent HPV vaccines due to overdue funding and insufficient on-site research funds, as communicated by health authorities in Shanxi and Jiangsu provinces [1][2] Group 1: Clinical Trial Suspension - The trivalent HPV vaccine (16/18/58 types) and the nine-valent HPV vaccine (6/11/16/18/31/33/45/52/58 types) clinical trials have been suspended due to overdue clinical trial funding [1] - The suspension is primarily due to the inability to continue gynecological visits necessary for the trials [1] Group 2: Impact on Clinical Trials - The trivalent HPV vaccine has already met the endpoint case collection requirements for its clinical protocol and is expected to have its market approval application accepted by April 2025, indicating that the suspension will not significantly impact this project [1] - The nine-valent HPV vaccine has completed the collection of cases for its primary endpoint and is currently in the process of accumulating secondary endpoint cases, but prolonged suspension may adversely affect this aspect [2] Group 3: Funding and Future Actions - The company is actively seeking funding through various channels to resolve overdue payments and resume normal clinical trial operations [2] - There is a risk that stakeholders may terminate the project if the company fails to make timely payments for overdue funding [2]

证券代码：920575 证券简称：康乐卫士 公告编号：2026-007 北京康乐卫士生物技术股份有限公司 关于三价和九价 HPV 疫苗临床试验暂停的公告 三、风险提示 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、临床试验暂停的原因 近日，北京康乐卫士生物技术股份有限公司（以下简称"公司"）收到山西 省疾病预防控制中心发送的《关于暂停重组三价和重组九价人乳头瘤病毒疫苗Ⅲ 期临床试验的函》及江苏省疾病预防控制中心发送的《关于暂停重组九价人乳头 瘤病毒疫苗Ⅲ期临床试验的函》。根据函件内容，由于公司临床试验经费支付逾 期，现场研究经费短缺，无法继续开展后续妇科访视工作。因此，山西省疾病预 防控制中心暂停公司重组三价人乳头瘤病毒（16/18/58 型）疫苗（大肠杆菌）（以 下简称"三价 HPV 疫苗"）和重组九价人乳头瘤病毒（6/11/16/18/31/33/45/52/58 型）疫苗（大肠埃希菌）（以下简称"九价 HPV 疫苗"）（女性适应症）Ⅲ期临床 试验，江苏省疾病预防控制中心暂停公司九价 HPV ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-006 北京康乐卫士生物技术股份有限公司 解除股权质押的公告 2026 年 1 月 15 日 （一） 本次解除股权质押基本情况 公司接到控股股东天狼星控股集团有限公司的通知，控股股东天狼星控股集 团有限公司本次解除股份质押 6,000,000 股，占其所持股份 9.93%，占公司总股 本 2.14%。本次解质的股份中，6,000,000 股为有限售条件股份，0 股为无限售 条件股份，解质的股份已在中国结算办理相关手续，解除日期为 2026 年 1 月 13 日。上述股份于 2024 年 12 月 31 日被质押，质押权人为中信银行股份有限公司 昆明分行。 （二） 剩余被质押股权的情况 截至公告披露日，公司控股股东天狼星控股集团有限公司剩余被质押的股份 为 27,455,697 股，占其所持股份的 45.43%，占公司总股本的 9.77%。剩余被质 押股份中，27,455,697 股为有限售条件股份，0 股为无限售条件股份。 二、 备查文件目录 中国证券登记结算有限责任公司出具的《解除证券质押登记通知》 北京康乐卫士生物技术股份有限公司 董事会 本 ...

证券之星消息，1月15日生物制品板块较上一交易日下跌0.82%，康乐卫士领跌。当日上证指数报收于 4112.6，下跌0.33%。深证成指报收于14306.73，上涨0.41%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688488 | 文迪药业 | 20.98 | 5.80% | 21.79万 | | 4.54亿 | | 603087 | 日李药业 | 72.55 | 4.69% | 16.82万 | | 12.25亿 | | 688293 | 奥浦迈 | 58.73 | 3.78% | 2.06万 | | 1.20亿 | | 688278 | 特宝生物 | 76.18 | 1.65% | 3.44万 | | 2.62亿 | | 688331 | 荣昌生物 | 104.90 | 1.51% | 10.51万 | | 11.06亿 | | 000534 | 万泽股份 | 22.18 | 1.32% | 12.60万 | | 2.78亿 | | 3 ...

Core Viewpoint - The trading volume on the Beijing Stock Exchange (BSE) reached 1.846 billion shares with a total transaction value of 45.769 billion yuan, reflecting a decrease of 2.280 billion yuan compared to the previous trading day. A total of 185 stocks closed higher, indicating a positive market sentiment [1]. Trading Performance - The number of stocks that closed higher was 185, accounting for 64.46% of the tradable stocks. Notable gainers included Keli Co., Ltd. (up 14.56%), Lian Di Information (up 13.48%), and Minshida (up 13.17%) [1]. - Conversely, 98 stocks closed lower, with significant declines seen in Xinganjiang (down 8.35%), Zhongcheng Technology (down 6.77%), and Kangle Health (down 6.42%) [1]. Transaction Details - A total of 139 stocks had transaction values exceeding 10 million yuan, with the highest transaction values recorded for Xingtou Measurement and Control (2.094 billion yuan), Liujin Technology (1.558 billion yuan), and Binhang Technology (1.228 billion yuan) [1]. - The trading activity showed that 78 stocks had a turnover rate exceeding 10%, with 18 stocks exceeding 20%. The highest turnover rates were observed in Liujin Technology (54.37%), Qifeng Precision (41.10%), and Zhongcheng Technology (41.00%) [1]. Stock Performance Summary - Key stocks with notable performance included: - Xingtou Measurement and Control: Closing price of 146.00 yuan, up 5.00%, turnover rate of 36.34%, transaction value of 2.094 billion yuan [1]. - Liujin Technology: Closing price of 13.57 yuan, up 29.98%, turnover rate of 54.37%, transaction value of 1.558 billion yuan [1]. - Binhang Technology: Closing price of 169.07 yuan, up 2.48%, turnover rate of 17.25%, transaction value of 1.228 billion yuan [1].

康乐卫士1月13日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 甬兴证券有限公司宁波和源路证券营业部 | 1768.50 | 0.00 | | 买二 | 东方财富证券股份有限公司拉萨东环路第二证券营业 | 1078.75 | 1131.47 | | | 部 | | | | 买三 | 东方证券股份有限公司昆明白龙路证券营业部 | 996.27 | 0.00 | | 买四 | 东吴证券股份有限公司苏州相城采莲路证券营业部 | 846.11 | 0.00 | | 买五 | 华安证券股份有限公司郑州陇海路营业部 | 822.59 | 0.00 | | 卖一 | 国金证券股份有限公司成都武成大街证券营业部 | 14.34 | 2759.29 | | 卖二 | 国投证券股份有限公司广州东风中路证券营业部 | 0.84 | 1318.91 | | 卖三 | 东方财富证券股份有限公司拉萨东环路第二证券营业 | 1078.75 | 1131.47 | | | 部 | | | | 卖四 | 国信证券股份有限公司深圳 ...

为满足公司日常生产经营及业务开展的需要,推动公司持续发展,公司控股 股东天狼星控股集团有限公司(以下简称"天狼星集团")为公司与上海斯丹姆 医药开发有限责任公司前期签署的临床试验相关合同项下 41,156,462.22 元费用 提供连带责任保证担保。 天狼星集团、公司实际控制人陶涛先生及其配偶为公司分别与广州金曼利医 药科技有限公司、金堤利醫藥(香港)有限公司及广州金域医学检验中心有限公 司前期签署的临床试验相关合同项下合计 32,118,245.80 元费用提供连带责任保 证担保。 二、关联方基本情况 中信证券股份有限公司 关于北京康乐卫士生物技术股份有限公司 接受关联方担保暨关联交易事项的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为北京康乐 卫士生物技术股份有限公司(以下简称"康乐卫士"、"公司")持续督导的保荐机 构,根据《证券发行上市保荐业务管理办法》《北京证券交易所上市公司持续监 管办法(试行)》《北京证券交易所证券发行上市保荐业务管理细则》《北京证券 交易所股票上市规则》等相关法律、法规和规范性文件的规定,对康乐卫士接受 关联方担保暨关联交易事项进行了核查,具体如下: ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-002 北京康乐卫士生物技术股份有限公司 关于接受关联方担保暨关联交易公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、关联交易概述 （一）关联交易概述 为满足北京康乐卫士生物技术股份有限公司（以下简称"公司"）日常生产 经营及业务开展的需要，推动公司持续发展，公司控股股东天狼星控股集团有限 公司（以下简称"天狼星集团"）为公司与上海斯丹姆医药开发有限责任公司前 期签署的临床试验相关合同项下 41,156,462.22 元费用提供连带责任保证担保。 天狼星集团、公司实际控制人陶涛先生及其配偶为公司分别与广州金墁利医 药科技有限公司、金墁利醫藥（香港）有限公司及广州金域医学检验中心有限公 司前期签署的临床试验相关合同项下合计 32,118,245.80 元费用提供连带责任保 证担保。 （二）决策与审议程序 公司于 2026 年 1 月 12 日召开了第五届董事会 2026 年第一次独立董事专门 会议、第五届董事会第十五次会议，审议通过 ...